Search Results - "KLEIN, Pamela M"

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor by YARDLEY, Denise A, ISMAIL-KHAN, Roohi R, MELICHAR, Bohuslav, LICHINITSER, Mikhail, MUNSTER, Pamela N, KLEIN, Pamela M, CRUICKSHANK, Scott, MILLER, Kathy D, LEE, Min J, TREPEL, Jane B

“…Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast…”
Get full text

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer by Romond, Edward H, Perez, Edith A, Bryant, John, Suman, Vera J, Geyer, Charles E, Davidson, Nancy E, Tan-Chiu, Elizabeth, Martino, Silvana, Paik, Soonmyung, Kaufman, Peter A, Swain, Sandra M, Pisansky, Thomas M, Fehrenbacher, Louis, Kutteh, Leila A, Vogel, Victor G, Visscher, Daniel W, Yothers, Greg, Jenkins, Robert B, Brown, Ann M, Dakhil, Shaker R, Mamounas, Eleftherios P, Lingle, Wilma L, Klein, Pamela M, Ingle, James N, Wolmark, Norman

“…A combined analysis of two large studies found that the addition of trastuzumab to chemotherapy with doxorubicin and cyclophosphamide plus paclitaxel improved…”
Get full text

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer by Dickler, Maura N, Cobleigh, Melody A, Miller, Kathy D, Klein, Pamela M, Winer, Eric P

“…Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally…”
Get full text

Concordance Between Central and Local Laboratory HER2 Testing from a Community-Based Clinical Study by Reddy, Josina C., Reimann, James D., Anderson, Steven M., Klein, Pamela M.

“…Women with HER2-overexpressing breast cancer have an unfavorable prognosis. Trastuzumab improves survival when combined with chemotherapy in the first-line…”
Get full text

Trastuzumab and cardiac dysfunction: update on preclinical studies by Klein, Pamela M, Dybdal, Noël

“…Trastuzumab, a humanized, recombinant antibody directed against HER2, can significantly improve survival in women with HER2-positive metastatic breast cancer…”
Get full text

Lavage and nipple aspiration of breast ductal fluids: A source of biomarkers for environmental mutagenesis by Klein, Pamela M., Lawrence, Julia A.

“…The acquisition of breast ductal fluid by nipple aspiration and ductal lavage are simple noninvasive procedures to sample breast tissue. Nipple aspiration…”
Get full text

Abstract LB122: The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1 by Hodges-Gallagher, Leslie, Parisian, Alison D., Sun, Richard, Myles, David C., Klein, Pamela M., Harmon, Cyrus L., Kushner, Peter J.

“…Abstract Estrogen receptor-positive (ER+) breast cancer can undergo metastatic spread to the brain, which occurs in up to 15% of HER2-/ER+ metastatic breast…”
Get full text

Abstract PS18-16: The complete estrogen receptor antagonist OP-1250 shrinks tumors in xenograft models and has favorable preclinical pharmacokinetic attributes by Hodges-Gallagher, Leslie, Sun, Richard, Myles, David C, Klein, Pamela M, Zujewski, Jo Anne, Harmon, Cyrus L, Kushner, Peter J

“…Abstract Antiestrogens are widely used to treat ER+, HER2- breast cancer however these may produce estrogen-like agonist effects in a cell and gene-specific…”
Get full text

Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer by Hamilton, Erika, Alemany, Carlos, Lin, Nancy U, Klein, Pamela M, Le, Trinh, Kushner, Peter J, Harmon, Cyrus, Zujewski, Jo Anne, Patel, Manish

“…Abstract Background: Endocrine therapy has been the primary treatment modality for HR+, HER2- metastatic breast cancer (MBC). Endocrine agents are administered…”
Get full text

Development of the breast cancer education and risk assessment program by Snyder, Laurel A, Soballe, Dawn B, Lahl, Lynda L, Nehrebecky, Michele E, Soballe, Peter W, Klein, Pamela M

“…To provide a description of the inception and evolution of the Breast Cancer Education and Risk Assessment Program. Computerized database (e.g., Personal…”
Get full text

Editorial by Josephy, P. David, Klein, Pamela M.

Get full text

Editorial by Josephy, P. David, Klein, Pamela M.

Get full text

Editorial by Josephy, P. David, Klein, Pamela M.

Get full text

Breast cancer and environmental mutagens: bridging molecular research to medicine and public health by JOSEPHY, P. David, KLEIN, Pamela M

Get full text

Female with Abdominal Pain and Neck Swelling by Klein, Pamela E., MD, Kapoor, Tushar, MD

Get full text